Ocular Therapeutix (OCUL) is back in focus after enrolling the first patient in its SOL-X long-term extension trial for AXPAXLI in wet age-related macular degeneration, alongside ongoing FDA discussions and New Drug Application preparations.

Despite the steady flow of clinical and regulatory updates around AXPAXLI, Ocular Therapeutix’s share price has been volatile, with an 11.07% 1 month share price return at a latest share price of US$9.43, a 20.22% decline year to date, and a 7.16% 1 year total shareholder return that sits alongside a 50.88% 3 year total shareholder return and a 41.97% 5 year total shareholder loss. This hints that sentiment has improved recently but remains shaped by changing perceptions of long term execution risk.

If this kind of clinical news has your attention, it could be a good time to see what else is moving in eye and drug discovery technology and check out 33 healthcare AI stocks

With OCUL trading at US$9.43 against a US$26 analyst target and carrying mixed long term returns, are you looking at an underappreciated wet AMD contender, or a name where future growth is already in the price?

Most Popular Narrative: 63.7% Undervalued

With Ocular Therapeutix last closing at $9.43 against a narrative fair value of $26, the widely followed view prices in a sizeable gap that all hinges on AXPAXLI’s long run potential and how that translates into revenue and margins over time.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see how this story tries to turn a single drug into a full retinal franchise? The core thesis leans on steep revenue ramps, rising margins and a rich future earnings multiple that is unusual for a loss making small cap today. Curious which assumptions have to hold together to bridge the gap from the current share price to that $26 fair value.

Under the narrative, future revenue growth, margin expansion and a premium earnings multiple all work together to justify that $26 figure, using a 6.978% discount rate to pull those future cash flows back into today’s terms. Analysts in this framework are effectively assuming that today’s losses of $265.9 million eventually flip to meaningful earnings, supported by AXPAXLI’s role in wet AMD and additional diabetic retinal indications, with the equity story also absorbing expected share count growth and ongoing R&D spend.

Result: Fair Value of $26 (UNDERVALUED)

However, this hinges on AXPAXLI clearing key clinical and regulatory hurdles, and any setback or weaker than expected uptake versus existing wet AMD therapies could quickly challenge that $26 narrative.

Another Take: High P/S Tells a Very Different Story

That $26 fair value leans heavily on future cash flows, but today’s pricing looks very different. Ocular Therapeutix trades on a P/S of 39.5x versus 5.3x for the US Pharmaceuticals industry and 1.7x across peers, while the fair ratio sits at just 0.1x. That is a wide gap and raises the question of whether expectations have already run too far ahead of current revenues.

For readers who prefer to stress test valuations using current market multiples rather than future cash flow models, it can be useful to see how the current P/S stacks up against a broad set of comparables, what the fair ratio implies, and how sensitive the story becomes if sentiment cools from here, which is where See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment divided between promise and risk, it helps to move quickly, review the details yourself, decide where you stand, and then weigh up the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If OCUL is on your radar, do not stop here. Use the same tools to spot other opportunities that could fit your portfolio before the crowd catches on.

• Target potentially overlooked quality by scanning screener containing 25 high quality undiscovered gems that pair solid fundamentals with room for the story to grow.
• Strengthen your core holdings by checking solid balance sheet and fundamentals stocks screener (44 results) for companies with healthier financial foundations.
• Put consistency first by reviewing 69 resilient stocks with low risk scores that aim to keep surprises to a minimum while you focus on long term compounding.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.